Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1

Abstract

Background: Leukocyte recruitment to areas of inflammation depends on Integrin-VCAM/ICAM interaction. Blocking the vascular cell adhesion molecule (VCAM-1) and the intracellular adhesion molecule (ICAM-1) may have therapeutic benefit for the inflammatory component of bowel disease. Notably, the induction of ICAM and VCAM is mediated by a nuclear factor kappaB (NF-κB)-dependent mechanism. We investigated whether the antiinflammatory properties of butyrate are mediated via the modulation of VCAM and ICAM on human endothelial cells. Methods: VCAM-1 and ICAM-1 expression on human endothelial cells upon tumor necrosis factor-α (TNF-α) stimulation was assessd by FACS analysis. A monocyte adhesion assay was performed to evaluate the relevance of a modulated CAM-expression. Electrophoretic mobility shift assays were applied to investigate NF-κB activation. Results: The observed butyrate-associated inhibition of monocyte adhesion to endothelial cells is associated with an inhibition of NF-κB activation in human endothelial cells. In this context, the observed suppression of the TNF-α induced VCAM-1 expression is likely to play an essential role. Conclusions: Butyrate inhibits VCAM-1 mediated leukocyte adhesion to human endothelial cells. This inhibition may contribute to the anti-inflammatory effects of butyrate in patients with distal ulcerative colitis. Copyright © 2004 by Lippincott Williams & Wilkins.